Portage Biotech Highlights Safety and Survival Data from Intensity Therapeutics' IT-01 Study of INT230-6 (PORT-1) at ASCO 2021 Annual Meeting
- Data from the IT-01 trial demonstrate the safety of INT230-6 (PORT-1) as both a monotherapy and in combination with checkpoint inhibitors in solid tumors - Survival data looks favorable compared to similar historical populations, balanced for prognostic factorsWestport, Connecticut--(Newsfile Corp. - June 2, 2021) - Portage Biotech Inc., (NASDAQ: PRTG) ("Portage" or the "Company") a ...